Huakui Yu Selected Research

Radiotherapy

1/2022	DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
10/2021	Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Huakui Yu Research Topics

Disease

7	Neoplasms (Cancer) 02/2022 - 10/2017
1	Fibrosis (Cirrhosis) 01/2022
1	Bites and Stings (Sting) 01/2022

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	DNA-Activated Protein KinaseIBA 01/2022
1	peposertibIBA 01/2022
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2022
1	fresolimumabIBA 01/2022
1	AntibodiesIBA 01/2018
1	CytokinesIBA 10/2017
1	avelumabIBA 10/2017

Therapy/Procedure

6	Therapeutics 02/2022 - 10/2017
3	Immunotherapy 02/2022 - 02/2019
2	Radiotherapy 01/2022 - 10/2021
1	Radioimmunotherapy 01/2022